📢 Just published! BIG’s Patient Partnership shows how people with lived experience can shape global breast cancer research. 🎀🌍 A model for research with patients, not just for them. BIG thank you to our patient partners! 💞 doi.org/10.1016/j.br...

📰 New in NEJM: Long-term results from the #SUPREMOtrial (BIG 2-04) show when postmastectomy radiotherapy may be safely avoided in “intermediate-risk” #breastcancer patients. A major step toward more tailored, less toxic treatment. www.nejm.org/doi/full/10....

At BIG, we support efforts to promote climate awareness and sustainability. 💚 Our Scientific Director, @virginieadam.bsky.social, travelled to #ESMO25 by train 🚊 in an effort to reduce the carbon footprint of congress attendance. #MyESMOstory 🧵

#ESMO25 ! poster 400P reports insights of a co-creation board composed of #breastcancer pts & health care providers on the barriers & actions to be taken to improve #deescalationtrial experience #Optimayoung @tanjaspanic.bsky.social @AliceFranzoi @unicancer @gustaveroussy.fr @EuropaDonnaEUR

Now at #ESMO25 ! #breastcancer poster session is open, results of an exploratory analysis of the #Lorelei trial exploring the impact of Body Mass Index on efficacy of #taselisib. Go check 349P @ChiaraDauccia @elisaagostinetto.bsky.social @ABCSGVienna @_SOLTI

#ESMO25 -PIK3CA helical mutations&enrichment of Macrophages2 predict response to #taselisib in #Lorelei pts. An increased response seen for pts w/ #Lobular #breastcancer treated w/ taselisib regardless of #PIK3CA status @ColletLaetitia @ABCSGVienna @SOLTI @oncoalert.bsky.social @oncodaily

Today at #ESMO25 ! @ColletLaetitia3 will give mini-oral presentation on the results of #RNAseq analysis of #Lorelei samples before & after #neoadjuvant treatment of HR+ HER2- BC with #taselisib . 116MO will be in room Cologne Auditorium-CityCube A. #ESMO @ABCSGVienna @_SOLTI

#ESMO25 The latest results from the #POSITIVE study show that temporary interruption of #endocrinetherapy for pregnancy does not add risk of #breastcancer recurrence at 6 yrs median FU. Most pts resumed ET per protocol. @etop_ibcsg @OncoAlert @oncodaily

Proffered paper presentation by Paul Cottu of the #RIBOLARIS trial at #ESMO25 showed that a subset of pts with HR+/HER2− eBC achieved ROR-low disease after neoadjuvant #ribociclib + #endocrinetherapy suggesting they could potentially avoid chemotherapy @_SOLTI @unicancer @OncoAlert

At the BIG Scientific Meeting @bigxresearch.bsky.social this morning, our Clinical Lead Prof @seamusoreilly.bsky.social presented to international colleagues in two sessions. We also heard updates on EXPERT and Path for Young. #BreastCancer #ESMO25

The BIG Scientific team has arrived in Berlin to attend #ESMO25. Congratulations #ESMO on the 50th anniversary! BIG has contributed to many #breastcancer presentations over the years. Excited for the#POSITIVE, #RIBOLARIS, #LORELEI results, & others this year!#myESMOStory

Today at #ESMO25, Dr. Fedro A Peccatori will present the updated results of #POSITIVEtrial after 5 years FU of pts w/ HR+ who have temporarily interrupted #endocrinetherapy to attempt #pregnancy. @etop_ibcsg

Our Assistant Operations Director, Dr @lisa-fox.bsky.social, is presenting the Greener Trials project at next week's @bigxresearch.bsky.social Pink October Webinar 2025. Find out more and register to attend here: bigagainstbreastcancer.org/events/big-p... #BreastCancer #GreenSky

Wonderful to meet with our colleagues from @LACOG_group and #GAICO at the 2025 BIG Scientific Meeting in Berlin. Together, we’re strengthening international collaboration to advance breast cancer research and improve outcomes for patients worldwide 🌎💗

Great to connect with members of BIG’s Patient Partnership Initiative during the 2025 BIG Scientific Meeting. @tanjaspanic.bsky.social , @evaschumacherwulf.bsky.social @christeeny513.bsky.social. Together, we’re working to ensure that patients’ voices help shape breast cancer research. 💗

Thank you @DrSoumenDasSurg and our colleague from India Dr. Tanmoy Kumar Mandal, who attended the BIG Scientific Meeting. Happy to see you all in person 🎀 😊

Welcome to our colleagues from Algeria, representing #BGICS, Prof Adda Bounedjar, Prof. Mohamed Oukkal, Prof Hassan Mahfouf and Prof Dib - thank you for your participation in the BIG Scientific Meeting! #SAFRO

Our BIG Executive Board member Dr. Ines Vaz Luis decentralized Clinical Trials and shared the example of @WeShare_Onco platform to the BIG groups at the BIG Scientific Meeting. @unicancer @GustaveRoussy

In the light of the emerging technologies in oncology, a talk was given by Dr. J. Kather, who presented at the BIG Scientific Meeting a keynote speech on #ArtificialIntelligence in #precisiononcology.

#BIGgroups representatives are meeting this morning in Berlin at the second 2025 BIG Scientific Meeting this year, a great opportunity to provide an update on the ongoing BIG studies and projects and discuss new proposals. #breastcancer

BIG is proud to be part of Europa Donna Breast Health Day 2025 led by @EuropaDonnaEUR. Patient advocates and policymakers @Europarl_EN met to promote prevention, early detection, health equity. Orsolya Birta & @Carmela_surgery reinforced BIG’s commitment to research & patients.

👋 Last week we welcomed Dr. Roberto Salgado to the BIG office to talk about his upcoming #SABCS25 presentation on BIG’s exploratory #APHINITY #TILs research. Stay tuned! Insights coming soon!

Yesterday at #BePrecise2025, @aftimosp highlighted #AURORA, an academic study led by @BIGxResearch & mainly supported by @BCRFCure. It identifies genetic changes in mBC—showcasing how molecular profiling drives #precisiononcology to guide treatment & improve outcomes @be__precise

Today, BIG’s team, Virginie Adam & Thayane Crestani, are at #BePrecise2025, where collaboration between clinicians & researchers highlights how #precisiononcology can enhance patient care: Cancer profiling, Targeted therapies, Multi-omics, AI & molecular imaging. @be__precise

🎉 The EXPERT trial has reached its recruitment target! Thanks to all the participants. This trial will be able to confirm if the Prosigna (PAM50) assay can identify women who may safely omit radiation therapy after breast cancer surgery. @BCTrialsANZ

New pub 📢 The #POSITIVEtrial manuscript led by @IDemeestere has been published in The Breast! It explores hormonal factors predictive of fertility in young women with #breastcancer interrupting #endocrinetherapy to try for pregnancy. @etop_ibcsg 🔗 www.thebreastonline.com/article/S096...

🙋‍♂️ How can we 📈 access to innovation for ALL patients with breast caner ❓ @bigxresearch.bsky.social commentary 📝👇 www.nature.com/articles/s41... 🙏 to co-authors✍️ Successes of the past ✅ Pitfalls of the present ✅ Solutions for the future eg OptimaYoung 👇

📢 New open-access article in npj Breast Cancer, co-authored by BIG’s leadership, explores the challenges of academic clinical trials and how to ensure their future impact. 📄 Read more: www.nature.com/articles/s41... #BIGAgainstBreastCancer #breastcancer #research

What an honor to join the Executive Board of @bigxresearch.bsky.social! As someone living w metastatic breast cancer & connected to many other patients, I’m excited to support research that reflects what truly matters to people dealing with this disease. 🔗 bigagainstbreastcancer.org/about-big/go...

Earlier this week, our team attended the first AI in Oncology conference in Paris, led by Prof. Fabrice André. A brilliant exchange on how AI is shaping cancer research and care. Thank you IHU PRISM for an inspiring first edition! #AIinOncology @PrismCenter

Our Scientific Advisor, Thayane Crestani, is attending the @EORTC Course on Clinical Trial Statistics for Non-Statisticians in Brussels, strengthening our team’s expertise to support better clinical research in breast cancer, from study design to data interpretation. 💡📊 📈

We are thrilled to announce a new collaboration with @paige_ai , leaders in AI-driven cancer digital pathology. Our partnership aims to combine BIG’s clinical trial expertise & data w Paige's AI capabilities to revolutionize #breastcancer research & care 🔗 bit.ly/4kzSsBd

🧬 BIG’s Scientific Director, Virginie Adam, spoke to RTBF about the results from #SERENA-6 presented at #ASCO25. A blood test to detect molecular recurrence + new treatment cut the risk of progression by 56%! 📖 Read more (in FR): www.rtbf.be/article/canc...

#SOFT&TEXT trials are the result of over 20 years of collaboration. Thank you to patients and their families, HC providers, study chairs and committees, collaborators, the cross-Atlantic groups & the funders. @etop_ibcsg @theNCI @BCRFcure #ASCO25

Happening NOW at #ASCO25 !! Poster presented by @GuiNaderMarta on long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the #ALTTOtrial ! Go check poster 135! @JulesBordet @DanaFarber @Harvard

Happening NOW at #ASCO25 !! Poster 119 presented by @KristinaFanucci on evaluation of treatment-related neutropenia as a predictor of response to adjuvant #palbociclib in the #PALLASTrial @ABCSGVienna @alliance_trials

TREAT ctDNA trial A BIG supporter study led by @EORTC compares #elacestrant vs. standard ET in ER+/HER2- BC pts with #ctDNA relapse. Enrollment is open in 12 countries and will involve 120 sites. Go check 210b TiP poster presented by @MIgnatiadis at #ASCO25. #bcsm

The voice of Early Career Investigators is heard at the #BIG-NCTN Annual Meetings, Drs @darioT_ and @io_zerdes are speaking on the need for #younginvestigators ' involvement and support in patient-centered #clinicalresearch. @theNCI @bcrfcure.bsky.social

#ASCO25: Assessment of #breastcancer Index benefit in #premenopausal pts receiving OFS-containing adjuvant #endocrinetherapy was compared btw #SOFT&TEXT cohorts and validation of the prognostic performance of BCI was conducted, go check Poster #150 @etop_ibcsg @oreganruth

Thank you to Dr. @BraunMDPhD for his great talk at the 2025 #BIG-NCTN Annual Meeting. Here, he explains how cancer vaccines work to treat cancer. @theNCI @BCRFcure @YaleCancer #ASCO25 #vaccines #breastcancer

Day 2 of the 2025 BIG-NCTN Annual Meeting in Chicago is ongoing to continue discussions on #breastcancer research and how joint efforts can be accomplished. @BCRFcure @theNCI

Day 1 of the BIG-NCTN Annual Meeting finishes with a dinner gathering all participants from both BIG and @theNCI networks and @BCRFcure leaders to celebrate the 20th Anniversary of the BIG_NCTN collaboration. @OncoAlert

New publication in the European Journal of Cancer: Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal pts with ER+ #breastcancer: A retrospective analysis of the #SOLE trial 🔗www.ejcancer.com/article/S0959-8049(25)00219-9/fulltext @OncologyAdvance

An abstract (e23009) has now been published at #ASCO25 on the BIG - Patient Partnership model for facilitating meaningful patient involvement in the design and conduct of cancer research, click here to read: meetings.asco.org/abstracts-pr...

#ESMObreast25 has come to a close with major insights from BIG studies. From long-term survival data to fertility and patient-reported outcomes, here are key takeaways from the event. #Aphinitytrial #Optimatrial #Positivetrial #ALTTOtrial #Pallastrial #ALPHABETtrial #BCSM

@TanjaSpanic at #ESMOBreast25 speaks about the importance of patients' involvement in #clinicalresearch @EORTC_QLG @EuropaDonnaEUR

Great to meeting you all in another day of #ESMOBreast25 Drs. Janice Tsang @aftimosp @BalicMarija @Carmela_surgery

Thank you to Dr. Janice Tsang for highlighting the importance of #survivorship in #breastcancer women, this very important to listen. #ESMOBreast25 #ESMO #BCSM

Thank you to Dr. Janice Tsang for highlighting the importance of #survivorship in #breastcancer women, this very important to listen. #ESMOBreast25 #ESMO #BCSM

#ESMOBreast25 Dr. Evangelia Razis, a BIG Executive Board member is talking about #LMD research in #breastcancer and mentioning the BIG Brain Metastasis task force and the BIG- #NCTN collaboration. @theNCI @BCRFcure